Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update

Oral Oncology

Volumn 45, Issue 7, 2009, Pages 551-554

  Bagan, Jose ^a,b   Scully, Crispian ^c,d,e   Sabater, Vicente ^b   Jimenez, Yolanda ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d WHO Collaborating Centre for Research   (United Kingdom)

^e Medical and Surgical Sciences   (United Kingdom)

Author keywords

Bisphosphonates; Cancer; Jaws; Osteonecrosis

Indexed keywords

AZITHROMYCIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CHLORHEXIDINE; CORTICOSTEROID DERIVATIVE; DOXYCYCLINE; LEVOFLOXACIN; METRONIDAZOLE; PAMIDRONIC ACID; PENICILLIN G; THALIDOMIDE; ZOLEDRONIC ACID;

BREAST CANCER; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DRUG POTENCY; HEREDITY; HUMAN; JAW OSTEONECROSIS; MAXILLOFACIAL SURGERY; MORBIDITY; MOUTH INFECTION; MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; TOOTH EXTRACTION; TREATMENT DURATION;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MULTIPLE MYELOMA; OSTEONECROSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 67449096723     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.01.002     Document Type: Review

References (43)

1. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 9 (2003) 1115-1117
2. Aapro M., Abrahamsson P.A., Body J.J., Coleman R.E., Colomer R., Costa L., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19 3 (2008) 420-432
3. Wutzl A., Biedermann E., Wanschitz F., Seemann R., Klug C., Baumann A., et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 30 9 (2008) 1224-1230
4. Novince CM, Ward BB, McCauley LK. Osteonecrosis of the jaw: an update and review of recommendations. Cells Tissues Organs 2008 [Epub ahead of print].
5. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 12 (2007) 2397-2410
6. Pazianas M., Miller P., Blumentals W.A., Bernal M., and Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29 8 (2007) 1548-1558
7. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 10 (2007) 1479-1491
8. Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and treatment. Ann Rev Med 2008 [Epub ahead of print].
9. Capsoni F., Longhi M., and Weinstein R. Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role. Arthritis Res Ther 8 5 (2006) 219
10. Alonci A., Allegra A., Bellomo G., Quartarone E., Oteri G., Nastro E., et al. Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1. Leuk Lymphoma 48 9 (2007) 1852-1854
11. Oteri G., Allegra A., Bellomo G., Alonci A., Nastro E., Penna G., et al. Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Cytokine 43 2 (2008) 103-104
12. Ruggiero S.L., and Drew S.J. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86 11 (2007) 1013-1021
13. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 6 (2008) 826-836
14. Wang E.P., Kaban L.B., Strewler G.J., Raje N., and Troulis M.J. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65 7 (2007) 1328-1331
15. Mavrokokki T., Cheng A., Stein B., and Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 3 (2007) 415-423
16. Stumpe MR, Chandra RK, Yunus F, Samant S. Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head Neck 2008 [Epub ahead of print].
17. Bagan J.V., Jimenez Y., Murillo J., Hernandez S., Poveda R., Sanchis J.M., et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 42 3 (2006) 327-329
18. Boonyapakorn T., Schirmer I., Reichart P.A., Sturm I., and Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44 9 (2008) 857-869
19. Carmagnola D, Celestino S, Abati S. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008 [Epub ahead of print].
20. Estilo C.L., Van Poznak C.H., Wiliams T., Bohle G.C., Lwin P.T., Zhou Q., et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 13 8 (2008) 911-920
21. Wessel J.H., Dodson T.B., and Zavras A.I. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66 4 (2008) 625-631
22. Borrás-Blasco J., Rosique-Robles D., Giner-Marco V., Galan-Brotons A., Casterá E., and Costa S. Possible delayed onset of osteonecrosis of the jaw in association with zoledrónico acid. J Clin Pharm Ther 32 6 (2007) 651-654
23. Sarasquete M.E., García-Sanz R., Marín L., Alcoceba M., Chillón M.C., Balanzategui A., et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112 7 (2008) 2709-2712
24. Lehrer S., Montazem A., Ramanathan L., Pessin-Minsley M., Pfail J., Stock R.G., et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106 3 (2008) 389-391
25. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66 6 (2008) 1320-1321 [author reply 1321-2]
26. Bagan JV, Jiménez Y, Gómez D, Sirera R, Poveda R, Scully C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 2008 [Epub ahead of print].
27. Ruggiero S.L., Fantasia J., and Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 4 (2006) 433-441
28. Bagan JV, Jimenez Y, Diaz JM, Murillo J, Sanchis JM, Poveda R. Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification. Oral Oncol 2008.
29. Junquera L., and Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?. J Oral Maxillofac Surg 66 7 (2008) 1516-1517
30. Bisdas S., Chambron Pinho N., Smolarz A., Sader R., Vogl T.J., and Mack M.G. Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 63 1 (2008) 71-77
31. García-Ferrer L., Bagán J.V., Martínez-Sanjuan V., Hernandez-Bazan S., García R., Jiménez-Soriano Y., et al. MRI of mandibular osteonecrosis secondary to bisphosphonates. AJR Am J Roentgenol 190 4 (2008) 949-955
32. Montebugnoli L., Felicetti L., Gissi D.B., Pizzigallo A., Pelliccioni G.A., and Marchetti C. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 4 (2007) 473-477
33. Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 2008 [Epub ahead of print].
34. Wutzl A., Biedermann E., Wanschitz F., Seemann R., Klug C., Baumann A., et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 30 9 (2008) 1224-1230
35. Longobardi G., Boniello R., Gasparini G., Pagano I., and Pelo S. Surgical therapy for osteonecotic lesions of the jaws in patients in therapy with bisphosphonates. J Craniofac Surg 18 5 (2007) 1012-1017
36. Freiberger J.J., Padilla-Burgos R., Chhoeu A.H., Kraft K.H., Boneta O., Moon R.E., et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 65 7 (2007) 1321-1327
37. Shimura K., Shimazaki C., Taniguchi K., Akamatsu S., Okamoto M., et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 84 4 (2006) 343-345
38. Nastro E., Musolino C., Allegra A., Oteri G., Cicciù M., Alonci A., et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 117 3 (2007) 181-187
39. Infante Cossío P., Cabezas Macián A., Pérez Ceballos J.L., Palomino Nicas J., and Gutiérrez Pérez J.L. Bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Med Oral Patol Oral Cir Bucal 13 1 (2008) E52-E57
40. Bagán J., Blade J., Cozar J.M., Constela M., García Sanz R., Gómez Veiga F., et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 12 4 (2007) E336-E340
41. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2008 [Epub ahead of print].
42. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2008 [Epub ahead of print].
43. Corso A., Varettoni M., Zappasodi P., Klersy C., Mangiacavalli S., Pica G., et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21 7 (2007) 1545-1548